Related Experiment Video

Updated: Jun 27, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.1K

The Clinical Impact of SARS-CoV-2 on Hypertrophic Cardiomyopathy

Danish Saleh1, Zhiying Meng2, Nicholas Johnson3

  • 1Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

Journal of Cardiovascular Development and Disease
|April 26, 2024
PubMed

Insights

COVID-19 infection significantly worsens outcomes for patients with Hypertrophic Cardiomyopathy (HCM). Infected HCM patients experienced higher rates of hospitalization, heart failure, myocardial injury, and mortality compared to uninfected HCM patients.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Genomics

Background:

  • Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition.
  • The clinical impact of SARS-CoV-2 (COVID-19) on HCM patients is not well understood.

Purpose of the Study:

  • To describe the clinical impact of COVID-19 infection in patients with HCM.
  • To compare outcomes of HCM patients with and without COVID-19.

Main Methods:

  • A retrospective analysis of 6.6 million patients in a Chicago healthcare system.
  • Identified adults with HCM and COVID-19 between 2019-2021.
  • Used propensity score matching for age, sex, BMI, and cardiovascular history.

Main Results:

  • HCM patients with COVID-19 had higher total hospitalizations (41.6 vs 23 per 100 persons).
  • Increased heart failure hospitalizations (24.2 vs 8.7), NSTEMI (8.6 vs 4.6), and mortality (10.8 vs 5) were observed in COVID-19 infected HCM patients.
  • Higher peak CRP levels were noted in HCM patients with COVID-19.

Conclusions:

  • COVID-19 infection is associated with increased myocardial injury in HCM patients.
  • HCM patients with COVID-19 experienced more total and heart failure hospitalizations.
  • COVID-19 infection is linked to increased mortality in the Hypertrophic Cardiomyopathy population.
Abstract

Keywords:
COVID-19Hypertrophic CardiomyopathySARS-CoV-2heart failuremortalitymyocardial injury

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.0K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.7K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
173
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
644
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422